Liquid biopsy in head neck cancer: ready for clinical routine diagnostics?
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
medline:
26
5
2023
pubmed:
27
3
2023
entrez:
26
3
2023
Statut:
ppublish
Résumé
The bodily fluids of patients with solid cancers representing a minimally-invasive source of clinically exploitable biomarkers have attracted an increasing amount of attention in recent years. In patients with head and neck squamous cell carcinoma (HNSCC), cell-free tumour DNA (ctDNA) belongs to the most promising liquid biomarkers for monitoring disease burden and identifying patients at high risk of recurrence. In this review, we highlight recent studies, evaluating the analytical validity and clinical utility of ctDNA as a dynamic biomarker in HNSCC, especially as it relates to risk stratification and contrasting human papilloma virus (HPV+ and HPV-) and carcinomas. The clinical potential of minimal residual disease monitoring through viral ctDNA in identifying HPV+ oropharyngeal carcinoma patients at higher risk of recurrence has recently been demonstrated. Furthermore, accumulating evidence supports a potential diagnostic value of ctDNA dynamics in HPV-negative HNSCC. Altogether, recent data suggest that ctDNA analysis may be a valuable tool in guiding (de)escalation of surgical interventions as well as adaptation in radiotherapy dosage, both in the definitive and adjuvant settings. Rigorous clinical trials with patient-relevant endpoints are critical in order to demonstrate that treatment decisions based on ctDNA dynamics result in better outcomes in HNSCC.
Identifiants
pubmed: 36966499
doi: 10.1097/CCO.0000000000000935
pii: 00001622-202305000-00003
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
151-157Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Mody MD, Rocco JW, Yom SS, et al. Head and neck cancer. Lancet 2021; 398:2289–2299.
Budach V, Tinhofer I. Novel prognostic clinical factors and biomarkers for outcome prediction in head and neck cancer: a systematic review. Lancet Oncol 2019; 20:e313–e326.
Moreira A, Masliah-Planchon J, Callens C, et al. Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets. Eur J Cancer 2019; 121:202–209.
Shaikh H, Karivedu V, Wise-Draper TM. Managing recurrent metastatic head and neck cancer. Hematol Oncol Clin North Am 2021; 35:1009–1020.
Balaji H, Demers I, Wuerdemann N, et al. Causes and consequences of HPV integration in head and neck squamous cell carcinomas: state of the art. Cancers (Basel) 2021; 13:4089.
Ho CM, Yang SS, Chien TY, et al. Detection and quantitation of human papillomavirus type 16, 18 and 52 DNA in the peripheral blood of cervical cancer patients. Gynecol Oncol 2005; 99:615–621.
Campitelli M, Jeannot E, Peter M, et al. Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients. PLoS One 2012; 7:e43393.
Jeannot E, Becette V, Campitelli M, et al. Circulating human papillomavirus DNA detected using droplet digital PCR in the serum of patients diagnosed with early stage human papillomavirus-associated invasive carcinoma. J Pathol Clin Res 2016; 2:201–209.
Chera BS, Kumar S, Beaty BT, et al. Rapid clearance profile of plasma circulating tumor HPV Type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer. Clin Cancer Res 2019; 25:4682–4690.
Chera BS, Kumar S, Shen C, et al. Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. J Clin Oncol 2020; 38:1050–1058.
Leung E, Han K, Zou J, et al. HPV sequencing facilitates ultrasensitive detection of HPV circulating tumor DNA. Clin Cancer Res 2021; 27:5857–5868.
Lam WKJ, Jiang P, Chan KCA, et al. Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma. Proc Natl Acad Sci U S A 2018; 115:E5115–E5124.
Chan DCT, Lam WKJ, Hui EP, et al. Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein-Barr virus DNA in posttreatment plasma. Ann Oncol 2022; 33:794–803.
Nawroz H, Koch W, Anker P, et al. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 1996; 2:1035–1037.
Carvalho AL, Jeronimo C, Kim MM, et al. Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res 2008; 14:97–107.
Flach S, Howarth K, Hackinger S, et al. Liquid BIOpsy for MiNimal RESidual DiSease detection in head and neck squamous cell carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma. Br J Cancer 2022; 126:1186–1195.
Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014; 20:548–554.
Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol 2016; 34:547–555.
Burgener JM, Zou J, Zhao Z, et al. Tumor-naive multimodal profiling of circulating tumor DNA in head and neck squamous cell carcinoma. Clin Cancer Res 2021; 27:4230–4244.
Schröck A, Leisse A, de Vos L, et al. Free-circulating methylated DNA in blood for diagnosis, staging, prognosis, and monitoring of head and neck squamous cell carcinoma patients: an observational prospective cohort study. Clin Chem 2017; 63:1288–1296.
Down TA, Rakyan VK, Turner DJ, et al. A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis. Nat Biotechnol 2008; 26:779–785.
Lee AWM, Lee VHF, Ng WT, et al. A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. Eur J Cancer 2021; 153:109–122.
Rettig EM, Wang AA, Tran NA, et al. Association of pretreatment circulating tumor tissue-modified viral HPV DNA with clinicopathologic factors in HPV-positive oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg 2022; 148:1120–1130.
Lydiatt WM, Patel SG, O'Sullivan B, et al. Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67:122–137.
Berger BM, Hanna GJ, Posner MR, et al. Detection of occult recurrence using circulating tumor tissue modified viral HPV DNA among patients treated for HPV-driven oropharyngeal carcinoma. Clin Cancer Res 2022; 28:4292–4301.
Yom SS, Torres-Saavedra PA, Kuperwasser C, et al. Association of plasma tumor tissue modified viral HPV DNA (TTMV) with tumor burden, treatment type, and outcome: a translational analysis from NRG-HN002. J Clin Oncol 2022; 40: abstr 6006.
Colevas AD. HPV DNA as a biomarker in oropharyngeal cancer: a step in the right direction. Clin Cancer Res 2022; 28:4171–4172.
Cao Y, Haring CT, Brummel C, et al. Early HPV ctDNA kinetics and imaging biomarkers predict therapeutic response in p16+ oropharyngeal squamous cell carcinoma. Clin Cancer Res 2022; 28:350–359.
Routman DM, Kumar S, Chera BS, et al. Detectable postoperative circulating tumor human papillomavirus DNA and association with recurrence in patients with HPV-associated oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2022; 113:530–538.
Flach S, Kumbrink J, Walz C, et al. Analysis of genetic variants of frequently mutated genes in human papillomavirus-negative primary head and neck squamous cell carcinoma, resection margins, local recurrences and corresponding circulating cell-free DNA. J Oral Pathol Med 2022; 51:738–746.
Henriksen TV, Reinert T, Christensen E, et al. The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA. Mol Oncol 2020; 14:1670–1679.
Tam M, Wu SP, Gerber NK, et al. The impact of adjuvant chemoradiotherapy timing on survival of head and neck cancers. Laryngoscope 2018; 128:2326–2332.
Graboyes EM, Garrett-Mayer E, Ellis MA, et al. Effect of time to initiation of postoperative radiation therapy on survival in surgically managed head and neck cancer. Cancer 2017; 123:4841–4850.
Galot R, van Marcke C, Helaers R, et al. Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncol 2020; 104:104631.
Wilson HL, D’Agostino RB Jr, Meegalla N, et al. The prognostic and therapeutic value of the mutational profile of blood and tumor tissue in head and neck squamous cell carcinoma. Oncologist 2021; 26:e279–e289.